Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study
By S. Chugh, Rasmus J. Havmoeller, K. Narayanan, David Singh, M. Rienstra, Emelia J. Benjamin, R. Gillum, Young-Hoon Kim, J. Mcanulty, Zhi‐Jie Zheng and 5 more. Circulation, 2013
4,178 citations recorded by the source corpus.
Background— The global burden of atrial fibrillation (AF) is unknown. Methods and Results— We systematically reviewed population-based studies of AF published from 1980 to 2010 from the 21 Global Burden of Disease regions to estimate global/regional prevalence, incidence, and morbidity and mortality related to AF (DisModMR software). Of 377 potential studies identified, 184 met prespecified eligibility criteria. The estimated number of individuals with AF globally in 2010 was 33.5 million (20.9 million men [95% uncertainty interval (UI), 19.5–22.2 million] and 12.6 million women [95% UI, 12.0–13.7 million]). Burden associated with AF, measured as disability-adjusted life-years, increased by 18.8% (95% UI, 15.8–19.3) in men and 18.9% (95% UI, 15.8–23.5) in women from 1990 to 2010. In 1990, the estimated age-adjusted prevalence rates of AF (per 100 000 population) were 569.5 in men (95% UI, 532.8–612.7) and 359.9 in women (95% UI, 334.7–392.6); the estimated age-adjusted incidence rates were 60.7 per 100 000 person-years in men (95% UI, 49.2–78.5) and 43.8 in women (95% UI, 35.9–55.0). In 2010, the prevalence rates increased to 596.2 (95% UI, 558.4–636.7) in men and 373.1 (95% UI, 347.9–402.2) in women; the incidence rates increased to 77.5 (95% UI, 65.2–95.4) in men and 59.5 (95% UI, 49.9–74.9) in women. Mortality associated with AF was higher in women and increased by 2-fold (95% UI, 2.0–2.2) and 1.9-fold (95% UI, 1.8–2.0) in men and women, respectively, from 1990 to 2010. There was evidence of significant regional heterogeneity in AF estimations and availability of population-based data. Conclusions— These findings provide evidence of progressive increases in overall burden, incidence, prevalence, and AF-associated mortality between 1990 and 2010, with significant public health implications. Systematic, regional surveillance of AF is required to better direct prevention and treatment strategies.
Subfields: Cardiology and Cardiovascular Medicine, Rheumatology
View Paper: https://www.semanticscholar.org/paper/8cb0d9ca0de5a91f1f5f4806c85ab40ade8b98b0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation (2017, neutral): “First, it is common: current estimates reveal that more than 33 million individuals worldwide have AF.(38) In the United States alone, it is estimated that between 3 and 5 million people have AF, and that by 2050 this number will exceed 8 million.”
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. (2016, neutral): “& The European Society of Cardiology 2016. All rights reserved. For permissions please email: journals.permissions@oup.com. doi:10.1093/eurheartj/ehw210 European Heart Journal (2016) 37, 2893–2962”
- Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). (2015, background): “9 million in the United States by 2050 (2,6,7).”
- Epidemiology of Atrial Fibrillation in the 21st Century, Novel Methods and New Insights (2020, methodology): “Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism”